Signos Raises $20 Million, Expands Dexcom Deal in GLP-1 Weight Loss Push
Updated
Updated · CNBC · May 27
Signos Raises $20 Million, Expands Dexcom Deal in GLP-1 Weight Loss Push
1 articles · Updated · CNBC · May 27
$20 million in new funding will help Signos deepen its push into GLP-1-linked weight loss, with backing from Google Ventures, Dexcom and Blue Cross Blue Shield of Alabama.
Dexcom also signed a distribution deal to place Signos subscription plans on its direct-to-consumer site, extending a partnership built around Dexcom's continuous glucose monitors.
Signos says its FDA-cleared 2025 platform uses AI to turn real-time glucose data into weight-loss guidance, and the new capital will expand predictive features such as meal scoring before users eat.
The startup is targeting both GLP-1 users and consumers seeking a standalone program, as demand for drugs like Wegovy and Zepbound surges in a market where JPMorgan expects 25 million Americans on GLP-1s by 2030.
Signos did not disclose its valuation, but said revenue and users each grew tenfold in the past six months and that tens of thousands have joined clinical studies.
Will AI biosensors become the standard partner for GLP-1 drugs or just a niche gadget in the weight-loss boom?
Can personal metabolic data solve the obesity crisis, or does it distract from fixing our food systems and public policy?
As AI predicts our food's effect, are we optimizing health or creating a new data-driven eating disorder?
Signos Secures $20M Funding to Expand AI-Powered Glucose Monitoring for Personalized Weight Management
Overview
In May 2026, Signos secured $20 million in funding led by major players like Google Ventures, Dexcom, and Blue Cross Blue Shield of Alabama, reflecting strong investor confidence and strategic alignment across technology, medical device, and insurance sectors. Signos aims to transform weight management by combining medication with personalized data, using continuous glucose monitoring (CGM) to deliver tailored insights and guidance. This approach supports a more holistic and effective solution for users, integrating real-time health data with medical interventions. The broad recognition from investors highlights Signos’ potential to reshape both consumer and medical health markets.